FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C. 20549
-------------	------------

heck this box if no longer subject
Section 16. Form 4 or Form 5
oligations may continue. See
ctruction 1(h)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>A2A Pharmaceuticals, Inc.</u>						2. Issuer Name and Ticker or Trading Symbol Biomea Fusion, Inc. [BMEA]										S. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner					
(Last)	(First) (Middle)					3. Date of Earliest Transaction (Month/Day/Year) 05/08/2023										Office belov	er (give title v)		Other (below)	(specify	
59 5TH AVE					4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street)															X Form filed by One Reporting Person						
NEW YO	ORK N	ORK NY 10003														Form filed by More than One Reporting Person					
(City) (State) (Zip)					Rı	Rule 10b5-1(c) Transaction Indication															
			Check t satisfy t	his box he affirr	to indi native	icate i defer	that a tr nse cor	ransa nditio	action was r ns of Rule 1	nade pu L0b5-1(d	rsuant to a c). See Instr	contra	act, instr 10.	uction or wri	tten pl	lan that is inte	ended to				
		Table	I - I	Non-Deriva	tive	Secu	rities	Acc	quir	ed, D	Disp	osed o	f, or I	3enefic	ially	Own	ed				
Date			2. Transaction Date (Month/Day/Ye	ar) E	2A. Deen Execution f any (Month/D	n Date,	Tr	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 ar				i)	Securi Benefi Owner	Securities For Beneficially (Downed Following In		Ownership rm: Direct) or direct (I) str. 4)	7. Nature of Indirect Beneficial Ownership		
								C	ode	v	Amount		(A) or (D)	Price				Transa	50.4)	(Instr. 4)	
Common Stock				05/08/2023		05/08/2023			S		10	0,000	D	\$33.9931(1)		3,800,000			D		
Common Stock 05/0				05/09/202	3	05/09/2		23 s			15	0,000	D	\$34.504	18 ⁽²⁾	3,650,000			D		
		Tal	ble	II - Derivati (e.g., pເ												Owne	d				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Exe if a	Deemed ecution Date, ny onth/Day/Year)		saction e (Instr.	str. Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			Date Ex piration pnth/Da te ercisab	n Date		Amo Secu Unde Deriv Secu 3 and	Amount or Number of	Der Sec	rice of ivative urity tr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Benefice Ownership (Instr. 4)	

Explanation of Responses:

- 1. A total of 100,000 shares were sold at an average price of 33.9931 in multiple transactions in a range of 33.01 to 34.855. Details of the specific transactions are available upon request.
- 2. A total of 150,000 shares were sold at an average price of 34.508 in multiple transactions in a range of 33.61 to 35.64. Details of the specific transactions are available upon request.

Edward Painter

05/10/2023

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.